uGDB, utilizing next-generation sequencing to detect bladder cancer-associated mutations and DNA alterations, has previously shown associations with recurrence and therapy response.

Press Release Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced a late-breaking poster presentation at the ...

Each pathway consists of several upstream regulators ... One downstream consequence of RB activity is the inhibition of E2F activity, which is important for the transcription of several genes ...

The poster will present new mechanistic insights into the anti-cancer activity of cyclin A/B RxL inhibitors, including their impact on DNA repair pathways and mitotic progression in E2F-high cancers.